Sham R L, Phatak P D, Belanger K A, Braggins C, Packman C H
Department of Medicine, Rochester General Hospital, NY 14621, USA.
Leuk Res. 1995 Aug;19(8):505-11. doi: 10.1016/0145-2126(95)00001-5.
All-trans retinoic acid (ATRA) is a differentiating agent that has been successfully used in the treatment of patients with acute promyelocytic leukemia (APL). Functional properties of peripheral blood neutrophils from a patient with APL during treatment with ATRA have been studied. Wright stain of patient neutrophils showed hypogranulation and loose nuclear chromatin when compared with normal neutrophils. These cells were of lower density than normal neutrophils and separated on density gradient centrifugation with mononuclear cells. Surface antigen expression by FACS distinguished these cells from lymphocytes. The histograms showed a population of larger cells expressing CD18 and CD11b, distinct from the smaller cells which did not express CD11b. fMLP caused an increase in intracellular calcium (measured spectrophotometrically) that was inhibited by the calcium chelator BAPTA. Actin polymerization following cell activation was measured using NBD-phallacidin staining and FACS. Both IL-8 and fMLP caused rapid increases using F-actin content (2.5-3.0 fold), which were of greater magnitude than generally seen with normal neutrophils. Treatment with BAPTA before activation with fMLP did not blunt the actin responses, despite complete inhibition of an intracellular calcium increase. In summary, neutrophils derives from differentiated APL cells express CD18/CD11b, and exhibit a similar degree of actin polymerization in response to fMLP and IL-8, independent of an increase in intracellular calcium. Although the actin responses are greater than normal neutrophils, most properties are similar, supporting the contention that these cells can protect the host. The exaggerated actin response to inflammatory mediators, however, may play a role in the 'retinoic acid syndrome'.
全反式维甲酸(ATRA)是一种分化诱导剂,已成功用于治疗急性早幼粒细胞白血病(APL)患者。对一名接受ATRA治疗的APL患者外周血中性粒细胞的功能特性进行了研究。与正常中性粒细胞相比,患者中性粒细胞的瑞氏染色显示颗粒减少和核染色质疏松。这些细胞的密度低于正常中性粒细胞,并在密度梯度离心时与单核细胞分离。通过流式细胞术检测表面抗原表达可将这些细胞与淋巴细胞区分开来。直方图显示一群表达CD18和CD11b的较大细胞,与不表达CD11b的较小细胞不同。fMLP导致细胞内钙增加(通过分光光度法测量),这被钙螯合剂BAPTA抑制。使用NBD-鬼笔环肽染色和流式细胞术测量细胞活化后的肌动蛋白聚合。IL-8和fMLP均导致F-肌动蛋白含量迅速增加(2.5 - 3.0倍),其增加幅度大于正常中性粒细胞通常所见。在用fMLP激活之前用BAPTA处理并没有减弱肌动蛋白反应,尽管细胞内钙增加被完全抑制。总之,源自分化的APL细胞的中性粒细胞表达CD18/CD11b,并且对fMLP和IL-8表现出相似程度的肌动蛋白聚合,与细胞内钙增加无关。尽管肌动蛋白反应大于正常中性粒细胞,但大多数特性相似,支持这些细胞可以保护宿主的观点。然而,对炎症介质的过度肌动蛋白反应可能在“维甲酸综合征”中起作用。